July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair
Studies Show a Sunny Outlook is Good for Health, Longer Life
ROCHESTER, Minn., July 22 /PRNewswire-USNewswire/ -- Here are highlights from the July issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo...
St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures
INDIANAPOLIS, July 8 /PRNewswire/ -- A surgeon at the St. Francis Heart
Center is using a revolutionary technology that allows patients to rebuild their own cardiovascular tissue.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090708/DE43062LOGO-a )
New Therapy Found to Prevent Heart Failure
ROCHESTER, N.Y., June 23 /PRNewswire-USNewswire/ -- A landmark study has successfully demonstrated a 29 percent reduction in heart
failure or death in patients with heart
disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) versus patients who recei...
New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients
Breakthrough findings unveiled at the American Society of Echocardiography's Scientific Sessions
WASHINGTON, June 8 /PRNewswire/ -- The American Society of Echocardiography (ASE) welcomes the world's leading researchers in cardiovascular medicine to present their most-recent findings at i...
Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
Data from Phase II/III Study Presented at Heart
Failure Congress 2009 Demonstrate Promising Safety and Efficacy Results for Relaxin
SAN MATEO¿ Calif.¿ June 1 /PRNewswire/ -- Corthera Inc. today announced that the results and additional statistical analyses conducted from Pre-RELAX-AHF, the Phase...
Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients;
Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers
SAN DIEGO, May 28 /PRNewswire/ -- Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneou...
Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
SAN MATEO¿ Calif.¿ May 28 /PRNewswire/ -- Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart
failure will be presented at the Heart
Failure Congress, the annual meeting of the Heart
Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
Phase 1/2 Calcium Upregulation by Percutaneous Administration (CUPID) Data Highlight Safety Profile and Biological Effects of SERCA2a Enzyme Replacement
SAN DIEGO, May 26 /PRNewswire/ -- Celladon Corporation today announced that results from its genetically targeted enzyme replacement therapy...
New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
- Four of the most commonly used proton pump inhibitors raise risk of heart
attack and stroke for patients taking Plavix(R) and increase healthcare costs
- Drug interaction increases annual hospital costs by nearly 40 percent
FRANKLIN LAKES, N.J., May 6 /PRNewswire-FirstCall/ -- Four ...
An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients
The results of the largest study performed to date will be presented during the International Society for Heart
and Lung Transplantation Annual Meeting in Paris, France on April 24, 2009
COLUMBIA, Md., April 24 /PRNewswire/ -- Since it was cleared as an in vitro assessment of cell-mediate...
Pistachios Offer Protective Benefits Against Heart Disease, Type II Diabetes and Obesity
Research Presented at Experimental Biology 2009 Reveals Cardiovascular and Glycemic Control Benefits of Pistachios
NEW ORLEANS, April 22 /PRNewswire/ -- Pistachios are much more than a great-tasting snack. The little green nuts may do more for your heart, blood sugar and waistline than many ...
Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
Sustained Benefits for Patients Awaiting Transplantation
ANN ARBOR, Mich., April 7 /PRNewswire/ -- The DuraHeart(TM) Left Ventricular Assist System (LVAS) shows sustained benefits in providing safe and reliable long-term circulatory support with an improved survival rate and an acceptable adv...
First Human Study to Show 'Sun Chlorella A' Supports Heart Health
RICHMOND, Va., March 30 /PRNewswire/ -- A new study, published in the Journal of Medicinal Food, showed that consumption of as little as 8 grams (1/3 ounce) of "Sun Chlorella A" daily resulted in noticeable reductions in body fat percentage, serum total cholesterol, and fasting blood glucose lev...
Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure
Data Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session; Results Published On-Line in The Lancet
SAN MATEO¿ Calif.¿ March 29 /PRNewswire/ -- Corthera Inc. today announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter,...
AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents
ROCKVILLE, Md., March 28 /PRNewswire-USNewswire/ -- Heart
disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart
attack than people fitted with stents not coated with medication, according to a new stu...
Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) today reported on an NIH-funded, pre-clinical study conducted by independent researchers at the University of Cincinnati entitled IGF-1--Overexpressing Mesenchymal Stem Cells Accelerate Bone Marrow Stem Cell ...
Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
SAN MATEO¿ Calif.¿ March 23 /PRNewswire/ -- Results from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart
failure will be presented at 10:30 a.m. EDT on Sunday, March 29, at the American College of Cardiology's (ACC...
New Aspirin Recommendation Can Help Prevent Heart Attacks & Strokes, Says Partnership for Prevention
WASHINGTON, March 16 /PRNewswire-USNewswire/ -- A new recommendation from the U.S. Preventive Services Task Force (USPSTF) underscores the value of regular aspirin use in preventing heart
attacks and strokes among many adults, the head of Partnership for Prevention said today.
The USPSTF foun...
Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
INDIANAPOLIS, Feb. 26 /PRNewswire-USNewswire/ -- America's pharmaceutical research and biotechnology companies are testing a record number of potential medicines to treat two of the country's top killers. According to the latest report by the Pharmaceutical Research and Manufacturers of America (P...
CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial
LAS VEGAS, Feb. 24 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two additional hospitals in the United States opened for patient enrollment for its ACORD Phase II clinical trial for the treatment of severe coronary heart
Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet
BOSTON, Feb. 17 /PRNewswire-USNewswire/ -- Women who adhere to a traditional Mediterranean diet -- high in monounsaturated fat, plant proteins, whole grains and fish -- are at a lower risk for stroke and coronary heart
disease, according to a study published this week in Circulation: Journal ...
American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
Association's Mission: Lifeline initiative to use survey data to make improvements
DALLAS, Feb. 16 /PRNewswire-USNewswire/ -- Preliminary results of one of the nation's largest national surveys of Emergency Medical Services (EMS) systems indicate the need for improvements in the way heart
Evidence Lacking in Multivitamin Study of Women's Risk of Cancer, Heart Disease or Death, Says Natural Products Association
WASHINGTON, Feb. 9 /PRNewswire-USNewswire/ -- A new study published today claiming that multivitamin use by postmenopausal women does little to improve their risk of mortality fails to take into account important dietary factors or accurately grasp how dietary supplements and health claims are reg...
February 2009 Mayo Clinic Women's HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus
Diabetes and Heart
Disease: Risk Intertwined
ROCHESTER, Minn., Feb. 4 /PRNewswire-USNewswire/ -- Here are highlights from the February issue of Mayo Clinic Women's HealthSource . You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required...
CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year
CVS Caremark Proactive Pharmacy Care approach designed to help improve medication adherence to positively impact outcomes and manage costs
WOONSOCKET, R.I., Feb. 3 /PRNewswire/ -- A study released today by CVS Caremark (NYSE: CVS ) found that nearly half of patients hospitalized for he...
Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
ROCHESTER, Minn., Feb. 2 /PRNewswire-USNewswire/ -- Men who experience erectile dysfunction between the ages of 40 and 49 are twice as likely to develop heart
disease than men without dysfunction, according to a new Mayo Clinic study.
Researchers also found that men with erectile dysfunction...
Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries
HOLLYWOOD, Fla., Jan. 19 /PRNewswire/ -- A new approach to unblocking heart
arteries minimally invasively will mean less bleeding, less down time, lower costs and less risk overall, particularly for obese patients, according to data being presented at the 21st annual International Symposium on End...
Implantable Defibrillators Lower Risk of Death in Older Heart Patients
Association rapid access journal report:
-- Implantable cardioverter defibrillators (ICDs) may reduce the risk of death by 30 percent in patients with reduced heart
-- This survival benefit applied to patients 75 years and older in t...
CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial
LAS VEGAS, Dec. 11 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two additional hospitals in the United States opened for patient enrollment for its ACORD Phase II clinical trial for the treatment of severe coronary heart
CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
LAS VEGAS, Nov. 25 /PRNewswire-FirstCall/ -- CardioVascular
BioTherapeutics, Inc. (OTC Bulletin Board: CVBT), announced today that it has
dosed the first patient in North America (NA) as part of its ACORD Phase II
clinical trial to treat patients with severe coronary heart
disease. The ACORD
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Phase 1 Data Demonstrate Safety and Improvement in Heart
Failure in a Majority of Patients
NEW ORLEANS, Nov. 9 /PRNewswire/ -- Celladon Corporation announced
today results from the first nine patients treated with MYDICAR(R), a
genetically-targeted enzyme replacement ...
Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
Long-term benefits of preventing heart
attacks highlighted in new study presented at global health outcomes meeting
ATHENS, Greece, Nov. 9 /PRNewswire-FirstCall/ -- Despite substantial
progress in the diagnosis and treatment of heart
prevention of recurrent heart
Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke
TOKYO, November 7 /PRNewswire/ --
- Large, International REACH Registry Also Shows Many Patients With
Atrial Fibrillation are Undertreated With Antiplatelet and Anticoagulant
A significant portion of patients with atherothrombosis also have
atrial fibrillation (AF), greatly incre...
Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola
Pharmaceuticals, a biopharmaceutical company developing innovative drugs
that provide significant advances in cardiovascular and inflammatory
diseases, and cancer, today announced that data relevant to betrixaban, the
company's novel ...
Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
Research shows that grape intake lowered blood pressure and signs of
heart muscle damage, and improved heart
function in lab rats
ANN ARBOR, Mich., Oct. 29 /PRNewswire-USNewswire/ -- Could eating
grapes help fight high blood pressure related to a salty diet? And could
grapes calm other facto...
HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
Landmark trial provides new insight for physicians
NATICK, Mass. and WASHINGTON, Oct. 15 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation (NYSE: BSX ) today announced results from an analysis
of the HORIZONS AMI trial. The HORIZONS AMI trial, sponsored by the
Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit
Institute Pioneers Research That May Offer New Hope to
Heart Failure Patients
PHOENIX, Oct. 8 /PRNewswire/ -- Nationally, over 3,000 people are
waiting for a heart
transplant - and a new lease on life. Sadly, only half
of those will receive a transplant. Now, pioneering researc...
American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for Depression
Studies show that depression is about three times more common in
patients following a heart
attack than in the general community.
patients should be screened for depression, and treated if
DALLAS, Sept. 30 /PRNewswire-USNewswire/ -- Heart
patients should be
screened for de...
American Heart Association Journal Report: Miniaturized Heart Pumps May Be Effective for Children Awaiting Transplant
In a small study, miniaturized heart
pumps helped keep children alive
who were awaiting a heart
The devices are not approved for general use in the United States.
DALLAS, Sept. 30 /PRNewswire-USNewswire/ -- In a recent study, nine
pediatric patients with sev...
American Heart Association Journal Report: Surgical Residents Perform Heart Surgery as Effectively as Staff Surgeons
* Success rates, safety and long-term outcomes of heart
surgery are not
significantly different when performed by properly supervised surgical
residents or staff surgeons.
* It is safe to include the training of residents even in complex
procedures. It is critical that tr...